AU2019392750B2 - Methods for treating or preventing gout or hyperuricemia - Google Patents

Methods for treating or preventing gout or hyperuricemia Download PDF

Info

Publication number
AU2019392750B2
AU2019392750B2 AU2019392750A AU2019392750A AU2019392750B2 AU 2019392750 B2 AU2019392750 B2 AU 2019392750B2 AU 2019392750 A AU2019392750 A AU 2019392750A AU 2019392750 A AU2019392750 A AU 2019392750A AU 2019392750 B2 AU2019392750 B2 AU 2019392750B2
Authority
AU
Australia
Prior art keywords
hyperuricemia
treating
methods
preventing gout
gout
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2019392750A
Other languages
English (en)
Other versions
AU2019392750A1 (en
Inventor
Rongzi YAN
Shunqi Yan
Litain YEH
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Arthrosi Therapeutics Inc
Original Assignee
Arthrosi Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Arthrosi Therapeutics Inc filed Critical Arthrosi Therapeutics Inc
Publication of AU2019392750A1 publication Critical patent/AU2019392750A1/en
Application granted granted Critical
Publication of AU2019392750B2 publication Critical patent/AU2019392750B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/343—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Dermatology (AREA)
  • Urology & Nephrology (AREA)
  • Pain & Pain Management (AREA)
  • Physiology (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Nutrition Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Furan Compounds (AREA)
AU2019392750A 2018-12-06 2019-12-05 Methods for treating or preventing gout or hyperuricemia Active AU2019392750B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862776251P 2018-12-06 2018-12-06
US62/776,251 2018-12-06
PCT/US2019/064785 WO2020118114A1 (en) 2018-12-06 2019-12-05 Methods for treating or preventing gout or hyperuricemia

Publications (2)

Publication Number Publication Date
AU2019392750A1 AU2019392750A1 (en) 2021-07-15
AU2019392750B2 true AU2019392750B2 (en) 2025-07-10

Family

ID=70974386

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2019392750A Active AU2019392750B2 (en) 2018-12-06 2019-12-05 Methods for treating or preventing gout or hyperuricemia

Country Status (13)

Country Link
US (1) US12419854B2 (enExample)
EP (1) EP3890722A4 (enExample)
JP (1) JP7528080B2 (enExample)
KR (1) KR102956127B1 (enExample)
CN (1) CN113164439A (enExample)
AU (1) AU2019392750B2 (enExample)
BR (1) BR112021010720A2 (enExample)
CA (1) CA3121624A1 (enExample)
EA (1) EA202191543A1 (enExample)
IL (1) IL283665A (enExample)
SG (1) SG11202105743RA (enExample)
TW (1) TW202038936A (enExample)
WO (1) WO2020118114A1 (enExample)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG11201900405XA (en) 2016-07-18 2019-02-27 Arthrosi Therapeutics Inc Compounds, compositions and methods for treating or preventing a sympton associated with gout or hyperuricemia
KR102946486B1 (ko) 2018-12-06 2026-03-31 아쓰로시 테라퓨틱스, 인크. 통풍 또는 고뇨산혈증의 치료 또는 예방을 위한 화합물의 결정형
WO2020118114A1 (en) 2018-12-06 2020-06-11 Arthrosi Therapeutics, Inc. Methods for treating or preventing gout or hyperuricemia
CN113368032A (zh) * 2020-07-23 2021-09-10 太阳升(亳州)生物医药科技有限公司 药物组合物、口服固体制剂及其制备方法和用途
TW202330485A (zh) * 2021-12-02 2023-08-01 美商安索治療公司 用於治療或預防痛風或高尿酸血症之化合物的結晶形式
US20250100988A1 (en) * 2021-12-30 2025-03-27 Arthrosi Therapeutics, Inc. Preparation of a compound for the treatment of gout or hyperuricemia

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018017368A1 (en) * 2016-07-18 2018-01-25 Arthrosi Therapeutics, Llc Compounds, compositions and methods for treating or preventing a sympton associated with gout or hyperuricemia

Family Cites Families (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4327725A (en) 1980-11-25 1982-05-04 Alza Corporation Osmotic device with hydrogel driving member
US4624848A (en) 1984-05-10 1986-11-25 Ciba-Geigy Corporation Active agent containing hydrogel devices wherein the active agent concentration profile contains a sigmoidal concentration gradient for improved constant release, their manufacture and use
US4968509A (en) 1987-07-27 1990-11-06 Mcneilab, Inc. Oral sustained release acetaminophen formulation and process
IL92966A (en) 1989-01-12 1995-07-31 Pfizer Dispensing devices powered by hydrogel
AU1537292A (en) 1991-04-16 1992-11-17 Nippon Shinyaku Co. Ltd. Method of manufacturing solid dispersion
AU661080B2 (en) 1991-11-22 1995-07-13 Warner Chilcott Company, Llc Risedronate delayed-release compositions
US5461140A (en) 1992-04-30 1995-10-24 Pharmaceutical Delivery Systems Bioerodible polymers for solid controlled release pharmaceutical compositions
US5323907A (en) 1992-06-23 1994-06-28 Multi-Comp, Inc. Child resistant package assembly for dispensing pharmaceutical medications
KR100291362B1 (ko) 1992-10-16 2001-09-17 니뽄 신야쿠 가부시키가이샤 왁스매트릭스의제법
US5686105A (en) 1993-10-19 1997-11-11 The Procter & Gamble Company Pharmaceutical dosage form with multiple enteric polymer coatings for colonic delivery
EP0827402A2 (en) 1995-05-17 1998-03-11 Cedars-Sinai Medical Center Compositions containing fatty acids for improving digestion and absorption in the small intestine
DE19624292A1 (de) 1996-06-18 1998-01-02 Merckle Gmbh Verfahren und Zwischenprodukte zur Herstellung von 1'-Hydroxybenzbromaron
US6395300B1 (en) 1999-05-27 2002-05-28 Acusphere, Inc. Porous drug matrices and methods of manufacture thereof
US6465014B1 (en) 2001-03-21 2002-10-15 Isp Investments Inc. pH-dependent sustained release, drug-delivery composition
JP4814789B2 (ja) 2004-06-10 2011-11-16 鳥居薬品株式会社 ６−ヒドロキシベンズブロマロン又はその塩からなる医薬組成物
US20080305169A1 (en) 2006-05-26 2008-12-11 Japan Tobacco Inc. Pharmaceutical Compositions Comprising Nitrogen-Containing Fused Ring Coumpounds
CN101765582A (zh) 2007-04-26 2010-06-30 奥斯拜客斯制药有限公司 氘标记的氯胺酮
BRPI0913129A2 (pt) * 2008-05-22 2016-01-05 Bristol Myers Squibb Co método para tratamento de hiperuricemia empregando um inibidor de sglt2 e composição contendo o mesmo
JP5325065B2 (ja) 2009-09-30 2013-10-23 株式会社富士薬品 新規フェノール誘導体
IT1400609B1 (it) * 2010-05-10 2013-06-14 Menarini Int Operations Lu Sa Associazione di inibitori della xantina ossidasi e metformina e loro uso.
JP5844376B2 (ja) 2010-10-06 2016-01-13 ジェイファーマ株式会社 強力な尿酸トランスポーター阻害剤の開発：それらの尿酸排泄効果のために設計された化合物
US20150031768A1 (en) 2011-08-19 2015-01-29 The Trustees Of Princeton University C-halogen bond formation
US9060987B2 (en) 2011-11-04 2015-06-23 Cymabay Therapeutics, Inc. Methods for treating gout flares
US9962362B2 (en) * 2012-03-29 2018-05-08 Children's Hospital Medical Center Use of small molecule inhibitors targeting EYA tyrosine phosphatase
WO2013152860A2 (en) 2012-04-11 2013-10-17 Dutalys Gmbh Improved antibody light chains
WO2013184572A1 (en) 2012-06-04 2013-12-12 Pharmacyclics, Inc. Crystalline forms of a bruton's tyrosine kinase inhibitor
JP6664219B2 (ja) 2012-08-14 2020-03-13 ミネルバ バイオテクノロジーズ コーポレーション 幹細胞増強治療法
BR112015013020A2 (pt) 2012-12-05 2017-07-11 Dutalys Gmbh método de geração de anticorpos biespecíficos, coleção de anticorpos ou seus fragmentos funcionais, de sequências de ácidos nucleicos, de vetores e de células hospedeiras, método de produção da coleção de anticorpos e de identificação de um anticorpo, anticorpo ou fragmento funcional e anticorpo biespecífico
WO2014113407A2 (en) * 2013-01-16 2014-07-24 Children's Hospital Medical Center Use of small molecule inhibitors targeting eya tyrosine phosphatase
EP2968235B1 (en) * 2013-03-15 2017-09-13 Janssen Pharmaceutica NV Combination of canagliflozin and probenecid for the treatment of hyperuricemia
US20140357683A1 (en) 2013-05-31 2014-12-04 Takeda Pharmaceuticals U.S.A., Inc. Methods of treatment and compositions with xanthine oxidase inhibitors
WO2015134467A1 (en) 2014-03-05 2015-09-11 The Trustees Of Princeton University Methods and compositions for direct radioactive labeling of bio-active molecules and building blocks
JP6571756B2 (ja) 2014-07-31 2019-09-04 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツングＭｅｒｃｋ Ｐａｔｅｎｔ Ｇｅｓｅｌｌｓｃｈａｆｔ ｍｉｔ ｂｅｓｃｈｒａｅｎｋｔｅｒ Ｈａｆｔｕｎｇ 神経変性疾患に適応可能なインドリジン誘導体
CN104262305B (zh) 2014-09-16 2016-06-08 东北制药集团股份有限公司 一种苯溴马隆晶型a及其制备方法
CN104311516B (zh) 2014-09-16 2017-01-11 东北制药集团股份有限公司 一种苯溴马隆晶型b及其制备方法
WO2018090921A1 (zh) 2016-11-16 2018-05-24 江苏新元素医药科技有限公司 Urat1抑制剂及其应用
CN109415333B (zh) 2016-12-14 2022-07-12 株式会社Lg化学 杂环化合物及包含其的有机发光元件
US20210130312A1 (en) 2018-04-03 2021-05-06 Children's Hospital Medical Center Inhibitors of eya3-protein tyrosine phosphatase in dna damage repair signaling of pulmonary arterial hypertension
BR112021006002A2 (pt) 2018-10-01 2021-06-29 Astrazeneca Ab composições para a redução de ácido úrico sérico
KR102946486B1 (ko) 2018-12-06 2026-03-31 아쓰로시 테라퓨틱스, 인크. 통풍 또는 고뇨산혈증의 치료 또는 예방을 위한 화합물의 결정형
WO2020118114A1 (en) 2018-12-06 2020-06-11 Arthrosi Therapeutics, Inc. Methods for treating or preventing gout or hyperuricemia
SG11202112562XA (en) 2019-05-14 2021-12-30 Arthrosi Therapeutics Inc Compound for treating gout or hyperuricemia
CN112952564B (zh) 2019-12-25 2022-04-22 华为数字能源技术有限公司 配电模块及通信电源系统
AU2021288679A1 (en) 2020-06-10 2023-02-02 Arthrosi Therapeutics, Inc. Methods for treating or preventing chronic kidney disease
CN112729156A (zh) 2020-12-24 2021-04-30 上海智能制造功能平台有限公司 一种人体数字化测量装置的数据拼接及系统标定方法
CN114697265A (zh) 2020-12-29 2022-07-01 华为技术服务有限公司 一种报文处理方法及装置
TW202330485A (zh) 2021-12-02 2023-08-01 美商安索治療公司 用於治療或預防痛風或高尿酸血症之化合物的結晶形式
US20250100988A1 (en) 2021-12-30 2025-03-27 Arthrosi Therapeutics, Inc. Preparation of a compound for the treatment of gout or hyperuricemia

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018017368A1 (en) * 2016-07-18 2018-01-25 Arthrosi Therapeutics, Llc Compounds, compositions and methods for treating or preventing a sympton associated with gout or hyperuricemia

Also Published As

Publication number Publication date
KR20210102933A (ko) 2021-08-20
CN113164439A (zh) 2021-07-23
IL283665A (en) 2021-07-29
EA202191543A1 (ru) 2021-10-26
CA3121624A1 (en) 2020-06-11
JP2022510303A (ja) 2022-01-26
AU2019392750A1 (en) 2021-07-15
US12419854B2 (en) 2025-09-23
BR112021010720A2 (pt) 2021-08-31
EP3890722A1 (en) 2021-10-13
SG11202105743RA (en) 2021-06-29
TW202038936A (zh) 2020-11-01
WO2020118114A1 (en) 2020-06-11
EP3890722A4 (en) 2022-08-24
US20220023251A1 (en) 2022-01-27
JP7528080B2 (ja) 2024-08-05
KR102956127B1 (ko) 2026-04-22

Similar Documents

Publication Publication Date Title
EP4041241A4 (en) METHODS OF TREATING MYELOFIBROSIS AND ASSOCIATED CONDITIONS
IL283665A (en) Methods for treating or preventing rheumatism or hyperuricemia
PT3348557T (pt) Imidazo[1,2a]piridinas para o tratamento ou prevenção de hiperuricemia ou gota
SG11202112562XA (en) Compound for treating gout or hyperuricemia
PT3484862T (pt) Compostos, composições e métodos para o tratamento ou a prevenção de um sintoma associado a gota ou hiperuricemia
EP3978546A4 (en) SURFACE TREATMENT AGENT
EP3609522A4 (en) METHODS AND COMPOUNDS FOR THE TREATMENT OF DIABETES
EP3733613A4 (en) SEWAGE TREATMENT PROCEDURES
EP3856241A4 (en) TREATMENT PROCESSES
EP3788078A4 (en) METHODS AND COMPOSITIONS FOR THE TREATMENT OF CHRONIC URTICARIA
ZA202007616B (en) Pharmaceutical composition for preventing or treating aids comprising rhodanine derivative
EP3804710A4 (en) MEANS OF PREVENTING OR IMPROVING NYCTURIA
EP3863606A4 (en) METHODS OF TREATMENT OR PREVENTION OF SKIN DISEASES
HK40008772A (en) Compounds, compositions and methods for treating or preventing a sympton associated with gout or hyperuricemia
HK40064299A (en) Methods for treating schizophrenia
HK40078477A (en) Methods for treating myelofibrosis and related conditions
HK40057850A (en) Methods for treating pancreatitis
HK40052135A (en) Method for the treatment of mucopolysaccharidosis type ii
HK40058936A (en) Treatment methods
HK40058935A (en) Treatment methods
AU2019901677A0 (en) Treatment Method
EP3778501A4 (en) Wastewater treatment method
AU2019904089A0 (en) Method for treating wastewater
HK40069414A (en) Processes and compounds
AU2019900083A0 (en) Treatment Method

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)